Is KPV a drug in these studies?

In the imaging work, no - it is a targeting group attached to a dye. In the nanoparticle work it is a targeting group on a carrier that also holds an actual drug, cyclosporine A, which is a licensed immunosuppressant. The tripeptide's role in both is to help the construct arrive somewhere.

Why is PepT1 overexpression useful for targeting?

Because targeting depends on a difference. A transporter present at low levels in healthy colon and induced during inflammation gives a construct a reason to accumulate in diseased tissue rather than everywhere, which is the central problem in delivery.

Does the 36-hour retention figure apply to KPV itself?

No. It describes how long the nanoparticle system persisted in inflamed tissue in that study. It says nothing about the tripeptide's own behaviour, which is a different molecule with different properties.

Does any of this relate to material sold here?

Only as literature. KPV is supplied here for laboratory research. The constructs described in these papers are purpose-built research materials made in academic laboratories, not products, and none of this work involves human use.

KPV

When the Tripeptide Is the Address, Not the Cargo

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

A distinct strand of the KPV literature does not use the tripeptide as an active agent at all. It attaches KPV to a fluorophore or a drug-loaded nanoparticle and uses its affinity for PepT1 to direct the construct toward cells that overexpress the transporter.

Key facts

Underlying property used: High affinity for PepT1
Why it works as an address: PepT1 is overexpressed in inflamed colonic epithelium
Fluorescent probe: DCM-KPV (Zeng M et al., 2017)
Probe outcome: Distinguished chronic, acute and normal groups
Nanoparticle system: CyA-PLGA-KPV/MMT/CS (Wu Y et al., 2019)
Target cells named: Colonic epithelial cells and macrophages
Retention in inflamed tissue: Up to 36 hours
Notable control result: The carrier without cyclosporine also showed effects

A different use for the same molecule

Most writing about KPV treats it as an agent: give the tripeptide, measure what changes. A growing part of the published work treats it as a postcode. If PepT1 is overexpressed on the surface of particular cells, and KPV binds PepT1 with high affinity, then attaching KPV to something else turns that something else into a molecule that preferentially reaches those cells. The tripeptide is not the point of the experiment; the delivery is.

The imaging application

Zeng and colleagues built a fluorescent probe by conjugating KPV to a dicyanomethylene-4H-pyran chromophore, producing DCM-KPV. The rationale is stated plainly in the paper: PepT1 is overexpressed in the colonic epithelial cells of chronic ulcerative colitis and can carry KPV into the cytosol, so the KPV moiety supplies a specific receptor-targeted interaction. The construct was reported to have long-wavelength emission, low photobleaching and negligible cytotoxicity, to accumulate in the cytoplasm and nucleus of an ulcerative colitis model in Caco-2 cells, and to distinguish chronic from acute ulcerative colitis and from normal tissue in animals. The paper also confirms, incidentally, what KPV is: the C-terminal sequence of alpha-MSH.

Research material referenced

KPV 10mg — third-party HPLC tested

View — £24.99

The drug delivery application

Wu and colleagues went further and used KPV to steer a therapeutic payload. Their system is a PLGA nanoparticle bearing KPV, coated with montmorillonite and chitosan, loaded with cyclosporine A. Each component has a stated job: the coating reduces leakage in the upper gastrointestinal tract and improves adhesion to inflamed colon, and the KPV supplies the targeting, described as directing the particle to colonic epithelial cells and macrophages via overexpressed PepT1. Biodistribution showed accumulation in inflamed tissue with retention up to 36 hours, and treated mice in a dextran sulfate sodium colitis model showed improvements in body weight, colon length and disease activity index.

The control result that complicates the story

That paper reports something that deserves more attention than it usually gets: the nanoparticle system without cyclosporine also produced marked effects. Read one way that is a bonus, and the authors treat it as intriguing. Read more carefully it is a problem for attribution. If the carrier alone does much of the work, then the experiment does not cleanly measure what the cyclosporine contributed, and it also does not cleanly measure what the KPV contributed, since the carrier includes both KPV and a mucoadhesive coating with its own physical effects on an inflamed surface. Untangling that would need arms the study did not run.

Why this strand matters for how KPV is described

It suggests that the most robust and reproducible thing about KPV is a transport property rather than a pharmacological one. Researchers reach for it because it reliably binds a transporter that is upregulated where they want to go. That is a real and useful characteristic, and it is a materially different claim from the one usually made about this molecule in retail copy. It also means that a paper with KPV in the title may not be a paper about KPV doing anything - it may be a paper about a dye or a nanoparticle that happens to wear KPV as a label.

How to read this literature

When a KPV paper appears, the first question is which role the tripeptide plays in it. If KPV is the intervention, the relevant controls are vehicle and, ideally, a transport-deficient condition. If KPV is a targeting moiety, the relevant control is the same construct without KPV, and the finding is about the construct. Conflating the two produces claims about a tripeptide that were really about a nanoparticle. None of this work involves humans, and none of it makes KPV a treatment for anything.

Extended research context

The KPV deep dive

Deep dive: two functions in one hormone, and the case for splitting them

Alpha-MSH is a thirteen-residue peptide cleaved from proopiomelanocortin, and it does two things that have almost nothing to do with each other. Its core sequence engages melanocortin receptors on melanocytes and drives melanin synthesis - the activity it is named for. Separately, it carries anti-inflammatory activity that Brzoska and colleagues localised to its C-terminal end, a paper titled 'terminal signal' precisely because the finding was that the signal sits at the terminus rather than in the receptor-binding core. That is an unusually clean functional separation, and it produced two research compounds pulling in opposite directions from one parent. KPV takes the C-terminal three residues and discards the pigmentation activity. Melanotan II does the reverse - a cyclic analogue built around the receptor-binding portion to maximise exactly what KPV was designed to leave behind. Same hormone, opposite halves.

Deep dive: what happens when you shrink a molecule fivefold

Going from alpha-MSH at 1,664.9 Da to KPV at 342.43 Da is not a trim, it is a change of category. A 1,665 Da peptide is firmly a cell-surface ligand - far too large to cross a membrane passively, so whatever it does must begin at a receptor. A 342 Da tripeptide is small enough that intracellular access becomes plausible, which is why KPV's reported mechanism is described in terms of NF-kappaB signalling rather than melanocortin receptor engagement. The consequence is rarely stated: if the fragment acts inside the cell and the parent acts at its surface, then the anti-inflammatory activity of the two is not necessarily the same phenomenon, and read-across between them should run cautiously in both directions. Fragment logic assumes the fragment is the parent minus something. Here it may be the parent minus something plus a different route of access.

Deep dive: the delivery paper is the most informative thing in the literature

Xiao and colleagues published in Molecular Therapy in 2017 on delivering KPV orally using hyaluronic acid-functionalised nanoparticles targeted to inflamed intestinal tissue. Read as a result it is a delivery success. Read as a statement about the compound it is more interesting: nobody builds a targeted nanoparticle carrier for a molecule that already reaches its target. The existence of that work says the free tripeptide's arrival at inflamed tissue was the limiting problem - which follows directly from being 342 Da, highly soluble and rapidly cleared. It is the same signal that CJC-1295's DAC modification carries for growth hormone secretagogues, or that lipidation carries across the whole incretin class: when the engineering effort goes into getting a compound to stay and arrive rather than into making it more active, the pharmacokinetics were the bottleneck.

Research applications

▸Melanocortin fragment structure-activity research
▸NF-kappaB pathway and cytokine production studies in culture
▸Murine models of induced intestinal inflammation
▸Targeted peptide delivery and carrier system development
▸Comparative work on parent hormones and isolated fragments
▸Analytical method development for very short peptides

Handling checklist

✓Verify identity against Lys-Pro-Val, CID 125672, at 342.43 Da
✓Do not search PubChem for 'KPV' - it returns an unrelated organic acid
✓Store lyophilised, cold, dry and dark
✓Use low-binding consumables; a small cationic peptide adsorbs to surfaces
✓Reconstitute gently down the vial wall and swirl, never shake
✓Aliquot into single-use volumes to avoid freeze-thaw cycling
✓Expect no disulfide or oxidation satellites - no cysteine, no methionine

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Searching PubChem for 'KPV' to verify a certificate

Fix: That returns CID 13294447, 2-oxo-5-phenylpentanoic acid at 192.21 Da, an unrelated compound. Search Lys-Pro-Val for CID 125672.

✗ Treating KPV and alpha-MSH findings as interchangeable

Fix: They differ fivefold in mass and the fragment may act intracellularly where the parent cannot. Read across cautiously in both directions.

✗ Assuming a colitis model result speaks to inflammatory bowel disease

Fix: Induced colitis in a mouse is acute and chemical; human IBD is chronic, heterogeneous and immunologically complex.

✗ Expecting to quantify KPV by absorbance at 280 nm

Fix: There is no aromatic residue in the sequence, so there is no usable absorbance there.

✗ Attributing unexplained low recovery to degradation

Fix: KPV is chemically robust - no cysteine, methionine or asparagine. Adsorption to glass and plastic is the more likely cause.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is KPV a drug in these studies?: In the imaging work, no - it is a targeting group attached to a dye. In the nanoparticle work it is a targeting group on a carrier that also holds an actual drug, cyclosporine A, which is a licensed immunosuppressant. The tripeptide's role in both is to help the construct arrive somewhere.
Why is PepT1 overexpression useful for targeting?: Because targeting depends on a difference. A transporter present at low levels in healthy colon and induced during inflammation gives a construct a reason to accumulate in diseased tissue rather than everywhere, which is the central problem in delivery.
Does the 36-hour retention figure apply to KPV itself?: No. It describes how long the nanoparticle system persisted in inflamed tissue in that study. It says nothing about the tripeptide's own behaviour, which is a different molecule with different properties.
Does any of this relate to material sold here?: Only as literature. KPV is supplied here for laboratory research. The constructs described in these papers are purpose-built research materials made in academic laboratories, not products, and none of this work involves human use.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum